Click on image to view larger version.

Figure 2 Landmark Analyses of Safety and Net Clinical Benefit

Landmark analyses (survival method) of the Kaplan-Meier estimates of Thrombolysis In Myocardial Infarction major noncoronary artery bypass grafting bleeding and net clinical benefit during the first 3 days after randomization (left side of each panel) and from 3 days to the end of the study (right side of each panel) are shown for the prasugrel and clopidogrel groups. There was no significant increase in major bleeding with prasugrel during the first 3 days, but there was a significant increase from 3 days to the end of the study. Net clinical benefit favored prasugrel during both the early and late phases of the study. HR = hazard ratio.